Loading clinical trials...
Loading clinical trials...
A Single-center, Open-label, Steady-state Drug-drug Interaction Study of SH229 Tablets and Daclatasvir Dihydrochloride Tablets in Healthy Subjects
Conditions
Interventions
SH229
SH229
+2 more
Locations
1
China
Phase I Clinical Trial Unit, The First Hospital of Jilin University
Changchun, Jilin, China
Start Date
November 19, 2018
Primary Completion Date
December 25, 2018
Completion Date
December 25, 2018
Last Updated
August 13, 2019
NCT07248826
NCT06159699
NCT03813875
NCT00621309
NCT02576366
NCT03686722
Lead Sponsor
Nanjing Sanhome Pharmaceutical, Co., Ltd.
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions